LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ)
- Previous Close
7.82 - Open
7.77 - Bid 7.79 x --
- Ask 7.80 x --
- Day's Range
7.77 - 7.90 - 52 Week Range
6.15 - 9.91 - Volume
1,843,400 - Avg. Volume
3,806,701 - Market Cap (intraday)
3.978B - Beta (5Y Monthly) --
- PE Ratio (TTM)
64.92 - EPS (TTM)
0.12 - Earnings Date --
- Forward Dividend & Yield 0.03 (0.39%)
- Ex-Dividend Date Jun 25, 2024
- 1y Target Est
--
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the Min Shan and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing and selling of Chinese herbal medicine pieces; and production and sales of medical devices such as protective masks. In addition, the company exports its products. LanZhou Foci Pharmaceutical Co.,Ltd. was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. is a subsidiary of Lanzhou Foci pharmaceutical industry development Group co., ltd.
www.fczy.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002644.SZ
View MorePerformance Overview: 002644.SZ
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002644.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002644.SZ
View MoreValuation Measures
Market Cap
3.98B
Enterprise Value
3.62B
Trailing P/E
65.13
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.31
Price/Book (mrq)
2.20
Enterprise Value/Revenue
3.93
Enterprise Value/EBITDA
53.08
Financial Highlights
Profitability and Income Statement
Profit Margin
6.13%
Return on Assets (ttm)
2.66%
Return on Equity (ttm)
3.44%
Revenue (ttm)
980.23M
Net Income Avi to Common (ttm)
60.07M
Diluted EPS (ttm)
0.12
Balance Sheet and Cash Flow
Total Cash (mrq)
397.89M
Total Debt/Equity (mrq)
1.52%
Levered Free Cash Flow (ttm)
29.84M